Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Other Non Operating Income (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Other Non Operating Income for 7 consecutive years, with $11.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 7.35% to $11.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $38.4 million, a 0.69% increase, with the full-year FY2025 number at $38.4 million, up 1.03% from a year prior.
  • Other Non Operating Income was $11.0 million for Q4 2025 at Kymera Therapeutics, up from $10.4 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $11.0 million in Q4 2025 to a low of $55000.0 in Q3 2021.
  • A 5-year average of $5.1 million and a median of $4.6 million in 2023 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: tumbled 65.52% in 2021, then surged 4092.55% in 2022.
  • Kymera Therapeutics' Other Non Operating Income stood at $94000.0 in 2021, then soared by 4092.55% to $3.9 million in 2022, then grew by 25.45% to $4.9 million in 2023, then skyrocketed by 107.36% to $10.3 million in 2024, then grew by 7.35% to $11.0 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Other Non Operating Income are $11.0 million (Q4 2025), $10.4 million (Q3 2025), and $8.1 million (Q2 2025).